定坤丹联合米非司酮对子宫内膜异位症患者疗效及相关血清指标水平的影响

Effect of Dingkundan Combined with Mifepristone on the Efficacy and Related Serum Indexes of Patients with Endometriosis

目的:研究定坤丹联合米非司酮对子宫内膜异位症患者疗效及相关血清指标水平的影响。方法:选择2017年6月~2019年6月96例子宫内膜异位症患者作为研究对象,随机分为两组(n=48),对照组接受米非司酮治疗,研究组接受定坤丹与米非司酮联合治疗。比较两组的癌抗原125(CA125)、癌抗原199(CA199)、抗子宫内膜抗体(EMAb)、血管内皮生长因子-A(VEGF-A)、成纤维细胞生长因子(bFGF)、转化生长因子-β1(TGF-β1)、视觉模拟评分(VAS)、临床疗效、不良反应。结果:治疗3个月后,研究组的CA125、CA199、EMAb、VEGF-A、bFGF、TGF-β1、VAS低于对照组,均有统计学差异(P<0.001)。研究组的总有效率(95.83%)高于对照组(83.33%),有统计学差异(P<0.05)。研究组的不良反应发生率(6.25%)与对照组(10.42%)无统计学差异(P>0.05)。结论:定坤丹联合米非司酮治疗可改善子宫内膜异位症患者的相关血清指标水平,提高临床疗效。

Objective:To study the effect of Dingkundan combined with mifepristone on the efficacy and related serum indexes of patients with endometriosis.Methods:Ninety-six patients with endometriosis from June2017 to June 2019 were selected as subjects,and they were randomly divided into the two groups(n=48).The control group was treated with mifepristone,and the study group was treated with Dingkundan combined with mifepristone.Cancer antigen 125(CA125),cancer antigen 199(CA199),anti-endometrial antibody(EMAb),vascular endothelial growth factor-A(VEGF-A),transforming growth factor-β1(TGF-β1),fibroblast growth factor(bFGF),visual analogue score(VAS),clinical efficacy and adverse reactions were compared between the two groups.Results:The CA125,CA199,EMAb,VEGF-A,bFGF,TGF-β1 and VAS in the study group after 3 months of treatment were significantly lower than those in the control group,and the differences were statistically significant(P<0.001).The total effective rate in the study group was 95.83%,which was significantly higher than the total effective rate in the control group(83.33%,P<0.05).The incidence of adverse reaction in the control group was 6.25%,and that in the study group was 10.42%,showing no significant difference(P>0.05).Conclusion:Dingkundan combined with mifepristone can improve the serum level of patients with endometriosis and improve clinical efficacy.